Bisphosphonates and radiation therapy for palliation of metastatic bone disease (Q35202905)

7 August 2017

1 reference

title

Bisphosphonates and radiation therapy for palliation of metastatic bone disease (English)

1 reference

adaptive radiation therapy

7 August 2017

main subject

0 references

author name string

Hoskin PJ

series ordinal

1

1 reference

7 August 2017

publication date

1 August 2003

1 reference

7 August 2017

published in

Cancer Treatment Reviews

1 reference

7 August 2017

volume

29

1 reference

7 August 2017

issue

4

1 reference

7 August 2017

page(s)

321-327

1 reference

Should bisphosphonates be part of the standard therapy of patients with multiple myeloma or bone metastases from other cancers? An evidence-based review

7 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(03)50013-6

7 January 2021

Radiotherapy for bone pain

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(03)50013-6

7 January 2021

Retreatment with radiotherapy for painful bone metastases

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(03)50013-6

7 January 2021

Palliation of bone metastases in prostate cancer. Hemibody irradiation or strontium-89?

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(03)50013-6

7 January 2021

A comparison of the palliative effects of strontium-89 and external beam radiotherapy in metastatic prostate cancer

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(03)50013-6

7 January 2021

Hemibody irradiation (HBI) for metastatic bone pain in two histologically distinct groups of patients

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(03)50013-6

7 January 2021

A prospective randomised trial of 4 Gy or 8 Gy single doses in the treatment of metastatic bone pain

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(03)50013-6

7 January 2021

The responsiveness of bone metastases to radiotherapy: the effect of site, histology and radiation dose on pain relief

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(03)50013-6

7 January 2021

Serum PICP as a bone formation marker in 89Sr and external beam radiotherapy of prostatic bony metastases

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(03)50013-6

7 January 2021

Effect of local radiotherapy for bone pain on urinary markers of osteoclast activity

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(03)50013-6

7 January 2021

Bisphosphonates for breast cancer.

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(03)50013-6

7 January 2021

The search for therapeutic gain in the combination of radiotherapy and chemotherapy

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(03)50013-6

7 January 2021

Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(03)50013-6

7 January 2021

Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(03)50013-6

7 January 2021

Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: results from a multinational randomized controlled trial. The Aredia Multinational Cooperative Group.

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(03)50013-6

7 January 2021

Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study Group

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(03)50013-6

7 January 2021

Efficacy of Pamidronate in Reducing Skeletal Events in Patients with Advanced Multiple Myeloma

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(03)50013-6

7 January 2021

Randomised, placebo-controlled multicentre trial of clodronate in multiple myeloma. Finnish Leukaemia Group

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(03)50013-6

7 January 2021

A randomized trial of the effect of clodronate on skeletal morbidity in multiple myeloma

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(03)50013-6

7 January 2021

A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(03)50013-6

7 January 2021

A report of RTOG 8206: a phase III study of whether the addition of single dose hemibody irradiation to standard fractionated local field irradiation is more effective than local field irradiation alone in the treatment of symptomatic osseous metast

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(03)50013-6

7 January 2021

Results of a randomized phase-III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer.

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(03)50013-6

7 January 2021

Concomitant i.v. and oral clodronate in the relief of bone pain – a double-blind placebo-controlled study in patients with prostate cancer

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(03)50013-6

7 January 2021

10.1016/S0305-7372(03)00013-6

Identifiers

DOI

1 reference

7 August 2017

1 reference